AC
CELZ icon

Armistice Capital’s Creative Medical Technology CELZ Stock Holding History

Armistice Capital’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148,000
Closed -$321K – 215
2025
Q1 		$321K Buy
+148,000
New +$516K ﹤0.01% 189
2022
Q3 		– Sell
-124,418
Closed -$933 – 206
2022
Q2 		$933 Buy
+124,418
New +$2.01M 0.02% 128

Other funds holding CELZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
AAS
Ameritas Advisory Services Lincoln, Nebraska $2.58B AUM 18.84% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital's CELZ Position: Q2 2025 in Review

Armistice Capital sold out of Creative Medical Technology (CELZ) in Q2 2025, closing a stake of 148,000 shares — an estimated $321K sold.

Armistice Capital first reported a position in CELZ in Q2 2022 and held it in 2 quarters. The position peaked at $321K in Q1 2025. 12 funds tracked by Wall St. Rank hold CELZ as of Q2 2025.

  • Armistice Capital reported no remaining Creative Medical Technology position as of Q2 2025 after selling out during the quarter.
  • Armistice Capital sold 148,000 Creative Medical Technology shares in Q2 2025, an estimated $321K.
  • Armistice Capital first reported a position in Creative Medical Technology in Q2 2022 and held it in 2 quarters.
  • Armistice Capital's Creative Medical Technology position peaked at $321K in Q1 2025.
  • 12 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2025.

Based on Armistice Capital's 13F filing for Q2 2025, filed 14 Aug 2025.